A published clinical-trial protocol is evidence of a research plan. It is not evidence that the planned intervention produced favorable outcomes. The 2025 KAPPA paper is a useful example because its carefully specified ketamine and psychotherapy program can easily be mistaken for a completed efficacy trial when summarized without its publication type.
What kind of paper was published?
Fletcher and colleagues published a protocol for an open-label, single-arm pilot involving a planned 20 adults seeking to reduce or stop methamphetamine use. The setting was a specialist outpatient service in Sydney. The paper explicitly stated that the study was not powered to determine efficacy.
The number 20 is a recruitment target in this document. It is not an analyzed sample, a completion count or a denominator for an observed adverse-event rate. Converting future-tense methods into past-tense results would fabricate evidence even if the proposed design were accurately described.
What intervention did the protocol specify?
The plan combined three weekly subcutaneous ketamine doses, 0.75–0.9 mg/kg according to tolerability, with four cognitive behavioral therapy sessions. One therapy session preceded dosing; three were scheduled within 24–48 hours after administrations. The treatment course covered four weeks.
Route and co-intervention are part of the research question. This protocol should not be cited as evidence for a different ketamine formulation or route, a single unaccompanied dose, or unsupervised use. The program tested as a package would also differ from a study designed to isolate ketamine’s independent contribution.
Which outcomes were primary concerns?
Safety and feasibility were to be assessed over eight weeks. Feasibility included recruitment, eligibility, completion, retention and acceptability. Secondary outcomes, including methamphetamine use, craving, withdrawal and quality of life, were planned over 24 weeks.
Feasibility asks whether a program can be implemented and studied in the proposed setting. Efficacy asks whether it improves an outcome relative to an appropriate comparison. Successful recruitment or good retention would be valuable findings without proving that the treatment itself reduced drug use.
Why do “open-label” and “single-arm” matter?
Participants and staff know the intervention, and there is no parallel randomized comparator in this design. If symptoms change during a later completed study, interpretation would need to consider expectations, psychotherapy, clinical contact, concurrent care and changes over time.
Those limitations do not make a pilot pointless. They define the stage of development and the questions it can answer. A pilot can identify delivery problems or safety observations that inform a subsequent comparative trial. It cannot supply the counterfactual outcome for the same participants without the intervention.
Does this article report KAPPA’s later results?
No. This commentary concerns the historical protocol published in February 2025. It does not assert the trial’s current recruitment status, completion status or subsequent findings.
When evaluating a treatment claim, check whether the cited document is a protocol, a results report or a secondary summary. Then identify the actual participant flow, comparator, prespecified endpoints and observed outcomes. For this paper, planned procedures and scientific rationale should remain clearly labeled as plans and hypotheses, with no invented efficacy or safety result.
Source
Fletcher K et al. Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial). BMJ Open. 2025;15(2):e092504. doi:10.1136/bmjopen-2024-092504. Full text. Published human trial protocol; no treatment results reported in this document.